A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
Sponsor: Pfizer
A PHASE4 clinical study on Smoking Cessation, this trial is completed. The trial is conducted by Pfizer and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Oct 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alexandria, Egypt , Austin, United States , Berlin, Germany , Brno, Czechia , Burnaby, Canada , Cairo, Egypt , Carina Heights, Australia , Castlemilk, United Kingdom , Chippenham, United Kingdom , Dafen, United Kingdom and 43 more locations